Please wait while the transcript is being prepared...
Nanotechnology in cancer and insulin therapy.
I am Professor Tejraj Aminabhavi, I did my PhD at the University of Texas, Austin USA.
I've published 849 papers in the nanotechnology field, I have an h-index of 98,
I have published three US patents, I am the editor of Chemical Engineering Journal.
I have expertise in polymer development, for drug delivery membrane science and wastewater treatment.
Nanotechnology is a ground-breaking field to explore and exploit numerous nanosystems,
that can offer multiple potential therapeutic benefits for the treatment of many chronic human diseases,
by site/target-specific delivery of therapeutics.
Recently, there have been a number of outstanding nanosystems developed for efficient drug delivery.
These nanosystems have been reported for the delivery of various drugs,
such as CNS drugs, cardiovascular drugs, antibiotics, anticancer drugs,
antiviral drugs, proteins, insulin, and so on.
These can be delivered through different routes of administration,
such as oral, nasal, ocular, transdermal, intravenous, and so on.
These systems are employed for targeted drug delivery to the brain, cancer, as well as colon delivery.
Recently, due to effective drug delivery, and preciseness of tumor sites or the microenvironment,
targeted drug delivery approaches have gained much importance for tumor metastasis therapy.
In fact, conventional treatments for metastasis therapy have many adverse effects,
since they kill carcinogenic cells but also healthy cells.
Tumor vasculature and angiogenesis has greatly depended upon growth and metastasis in tumors,
so various nanocarrier-based delivery approaches for targeting tumor vasculature are used
for the treatment of tumor metastases, and associated lesions.
Targeted drug delivery can overcome limitations and adverse effects associated with conventional therapies.